JP2022528851A5 - - Google Patents

Info

Publication number
JP2022528851A5
JP2022528851A5 JP2021557758A JP2021557758A JP2022528851A5 JP 2022528851 A5 JP2022528851 A5 JP 2022528851A5 JP 2021557758 A JP2021557758 A JP 2021557758A JP 2021557758 A JP2021557758 A JP 2021557758A JP 2022528851 A5 JP2022528851 A5 JP 2022528851A5
Authority
JP
Japan
Prior art keywords
formula
residue
val
cit
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021557758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022528851A (ja
JP7210770B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/057984 external-priority patent/WO2020200880A1/en
Publication of JP2022528851A publication Critical patent/JP2022528851A/ja
Publication of JP2022528851A5 publication Critical patent/JP2022528851A5/ja
Priority to JP2023002495A priority Critical patent/JP7680658B2/ja
Application granted granted Critical
Publication of JP7210770B2 publication Critical patent/JP7210770B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021557758A 2019-03-29 2020-03-23 化合物及びその複合体 Active JP7210770B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023002495A JP7680658B2 (ja) 2019-03-29 2023-01-11 化合物及びその複合体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962826393P 2019-03-29 2019-03-29
US62/826,393 2019-03-29
US202062964177P 2020-01-22 2020-01-22
US62/964,177 2020-01-22
PCT/EP2020/057984 WO2020200880A1 (en) 2019-03-29 2020-03-23 Compounds and conjugates thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023002495A Division JP7680658B2 (ja) 2019-03-29 2023-01-11 化合物及びその複合体

Publications (3)

Publication Number Publication Date
JP2022528851A JP2022528851A (ja) 2022-06-16
JP2022528851A5 true JP2022528851A5 (cg-RX-API-DMAC7.html) 2022-08-24
JP7210770B2 JP7210770B2 (ja) 2023-01-23

Family

ID=69960637

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557758A Active JP7210770B2 (ja) 2019-03-29 2020-03-23 化合物及びその複合体
JP2023002495A Active JP7680658B2 (ja) 2019-03-29 2023-01-11 化合物及びその複合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023002495A Active JP7680658B2 (ja) 2019-03-29 2023-01-11 化合物及びその複合体

Country Status (30)

Country Link
US (3) US20220211863A1 (cg-RX-API-DMAC7.html)
EP (2) EP3946464B1 (cg-RX-API-DMAC7.html)
JP (2) JP7210770B2 (cg-RX-API-DMAC7.html)
KR (3) KR20240104214A (cg-RX-API-DMAC7.html)
CN (4) CN118240003A (cg-RX-API-DMAC7.html)
AU (1) AU2020252034B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021018986A2 (cg-RX-API-DMAC7.html)
CA (1) CA3133757A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002498A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014566A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210541A (cg-RX-API-DMAC7.html)
DK (1) DK3946464T3 (cg-RX-API-DMAC7.html)
EA (1) EA202192554A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP21078204A (cg-RX-API-DMAC7.html)
ES (1) ES2930295T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20221280T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060364T2 (cg-RX-API-DMAC7.html)
IL (1) IL286291B2 (cg-RX-API-DMAC7.html)
LT (1) LT3946464T (cg-RX-API-DMAC7.html)
MX (1) MX2021011812A (cg-RX-API-DMAC7.html)
PH (1) PH12021552363A1 (cg-RX-API-DMAC7.html)
PL (1) PL3946464T3 (cg-RX-API-DMAC7.html)
PT (1) PT3946464T (cg-RX-API-DMAC7.html)
RS (1) RS63715B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110524VA (cg-RX-API-DMAC7.html)
SM (1) SMT202200439T1 (cg-RX-API-DMAC7.html)
TW (2) TWI886667B (cg-RX-API-DMAC7.html)
UA (1) UA129129C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020200880A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202106612B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
US11493668B2 (en) 2018-09-26 2022-11-08 Johnson & Johnson Vision Care, Inc. Polymerizable absorbers of UV and high energy visible light
KR20240104214A (ko) * 2019-03-29 2024-07-04 메디뮨 리미티드 화합물 및 이의 접합체
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
US20230097908A1 (en) * 2020-01-22 2023-03-30 Medimmune Limited Compounds and conjugates thereof
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
TW202140076A (zh) * 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
AU2022216696A1 (en) * 2021-02-05 2023-08-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
EP4389732A4 (en) 2021-08-17 2025-08-27 Jiangsu Mabwell Health Pharmaceutical R&D Co Ltd PROCESS FOR THE SYNTHESIS OF 5,8-DIAMINO-3,4-DIHYDRO-2H-1-NAPHTHALENONE AND INTERMEDIATE COMPOUND USED IN THIS PROCESS
CN118414339A (zh) * 2021-12-16 2024-07-30 迈威(上海)生物科技股份有限公司 一种喜树碱类化合物及其偶联物
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
KR20240159839A (ko) 2022-03-09 2024-11-06 아스트라제네카 아베 FRα에 대한 결합 분자
EP4490517A1 (en) 2022-03-11 2025-01-15 Astrazeneca AB A scoring method for an anti-fr alpha antibody-drug conjugate therapy
MX2024011519A (es) 2022-03-23 2024-09-24 Synaffix Bv Conjugados de anticuerpos para el direccionamiento contra tumores que expresan el antigeno carcinoembrionario.
IL315366A (en) 2022-03-23 2024-11-01 Synaffix Bv Antibody pairs for targeting PTK7-expressing tumors
US20250205353A1 (en) 2022-03-23 2025-06-26 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing nectin-4
CA3253220A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. ANTIBODIES CONJUGATED FOR TARGETING TUMORS EXPRESSING TROP-2
KR20240162575A (ko) 2022-03-25 2024-11-15 자임워크스 비씨 인코포레이티드 엽산 수용체 알파를 표적화하는 항체-약물 접합체 및 사용 방법
CN115160403B (zh) * 2022-07-05 2025-06-27 博石丰生命科技(南通)有限公司 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法
WO2024051762A1 (en) * 2022-09-07 2024-03-14 Xadcera Biopharmaceutical (Suzhou) Co., Ltd. Anti-trop2/egfr antibodies and uses thereof
TW202448517A (zh) 2023-02-16 2024-12-16 瑞典商阿斯特捷利康公司 用治療性結合分子治療癌症的組合療法
EP4701665A1 (en) 2023-04-28 2026-03-04 MedImmune Limited B7-h4 therapeutic binding molecules for the treatment of cancer
IL324453A (en) * 2023-05-12 2026-01-01 Biocytogen Pharmaceuticals Beijing Co Ltd Binding agent compounds and ligand-drug conjugates, methods of preparation and uses thereof
EP4721767A1 (en) 2023-06-05 2026-04-08 Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. Anti-b7-h3 antibody or fragment thereof, and antibody drug conjugate targeting b7-h3
KR20260048598A (ko) 2023-07-31 2026-04-10 아스트라제네카 아베 Cd123 항체-약물 접합체 및 이의 사용 방법
TW202540115A (zh) * 2023-11-16 2025-10-16 大陸商上海齊魯製藥研究中心有限公司 一種氘代喜樹鹼化合物及其製備和應用
CN122374343A (zh) 2023-11-30 2026-07-10 江苏康宁杰瑞生物制药有限公司 包含pd-l1结合分子与双特异性抗体-药物偶联物的组合物及其用途
AU2024415931A1 (en) 2023-12-27 2026-07-16 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Multi-specific antibody targeting her3 and trop2 and conjugate thereof
AU2025220091A1 (en) * 2024-02-06 2026-08-06 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug conjugate, preparation method therefor, and use thereof
CN122580121A (zh) * 2024-02-06 2026-08-14 四川科伦博泰生物医药股份有限公司 抗体药物偶联物及其制备方法和用途
WO2025191470A1 (en) 2024-03-12 2025-09-18 Astrazeneca Ab Processes and compounds for the preparation of topoisomerase i inhibitor linker-payloads
WO2026057740A1 (en) 2024-09-12 2026-03-19 Astrazeneca Ab Treatment of cancer with therapeutic binding molecules
WO2026078620A1 (en) 2024-10-11 2026-04-16 Medimmune Llc Cd22 antibody and drug conjugates and uses thereof
WO2026115454A2 (en) 2024-11-27 2026-06-04 Astrazeneca Ab Claudin 18.2 antibodies, antigen binding fragments and antibody drug conjugates thereof and methods of use in cancer therapy

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4939255A (en) 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
JP2754022B2 (ja) * 1988-11-18 1998-05-20 第一製薬株式会社 カンプトテシン類縁体
JP3024013B2 (ja) * 1990-08-14 2000-03-21 杏林製薬株式会社 フルオロエチルカンプトテシン誘導体
JP3008226B2 (ja) * 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
US6407115B1 (en) 1991-01-16 2002-06-18 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
US5658920A (en) 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
DK0811603T3 (da) 1995-02-22 2002-12-16 Daiichi Seiyaku Co Aminotetralonderivater og fremgangsmåder til fremstilling af samme
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
US5663177A (en) 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
JPH1095802A (ja) * 1995-12-28 1998-04-14 Tanabe Seiyaku Co Ltd カンプトテシン誘導体
IN189180B (cg-RX-API-DMAC7.html) 1997-07-09 2003-01-04 Chong Kun Dang Corp
AR030207A1 (es) 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
US6403604B1 (en) * 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6737548B2 (en) 2001-05-08 2004-05-18 Mitsui Chemicals, Inc. Process for preparing 1,5-diaminonaphthalene derivative
UA80409C2 (en) 2001-11-30 2007-09-25 Chugai Pharmaceutical Co Ltd Hexacyclic compounds
WO2004073601A2 (en) 2003-02-21 2004-09-02 Chugai Seiyaku Kabushiki Kaisha Process for the preparation of hexacyclic camptothecin derivatives
US7910593B2 (en) 2004-04-09 2011-03-22 Chugai Seiyaku Kabushiki Kaisha Water-soluble prodrugs
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
DK1813614T3 (da) 2006-01-25 2012-01-23 Sanofi Sa Cytotoksiske midler, der omfatter nye tomaymycinderivater
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
BRPI0818780A2 (pt) 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
WO2012096832A2 (en) * 2011-01-12 2012-07-19 Crystal Biopharmaceutical Llc Hdac inhibiting derivatives of camptothecin
CN102850400A (zh) * 2011-06-30 2013-01-02 周文强 喜树碱衍生物及其制备方法、药物组合物与用途
US10195288B2 (en) * 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
WO2014121033A1 (en) * 2013-02-04 2014-08-07 Fl Therapeutics Llc Soluble complexes of drug analogs and albumin
CN115504924A (zh) * 2013-11-27 2022-12-23 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
SG10201902571VA (en) 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗cd98抗体−薬物コンジュゲート
TWI871999B (zh) 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
US11185594B2 (en) 2014-04-10 2021-11-30 Daiichi Sankyo Company, Limited (Anti-HER2 antibody)-drug conjugate
EP3733209A1 (en) 2014-10-03 2020-11-04 Synaffix B.V. Sulfamide linker, conjugates thereof, and methods of preparation
CN114716506A (zh) 2015-01-30 2022-07-08 苏特罗生物制药公司 用于偶联和治疗的哈米特林(hemiasterlin)衍生物
GB201506393D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
CA2990572C (en) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
MA43354A (fr) * 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2018066626A1 (ja) 2016-10-07 2018-04-12 第一三共株式会社 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療
US20190367605A1 (en) 2016-11-10 2019-12-05 Medimmune, Llc Binding Molecules Specific For ASCT2 And Uses Thereof
JPWO2018110515A1 (ja) 2016-12-12 2019-10-24 第一三共株式会社 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
SG11201906554RA (en) 2017-01-17 2019-08-27 Daiichi Sankyo Co Ltd Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
US12667557B2 (en) 2017-02-28 2026-06-30 Daiichi Sankyo Company, Limited Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate
TWI926682B (zh) 2017-05-15 2026-05-21 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
CN109106951A (zh) 2017-08-18 2019-01-01 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
WO2019034177A1 (zh) 2017-08-18 2019-02-21 四川百利药业有限责任公司 具有两种不同药物的抗体药物偶联物
KR20240104214A (ko) * 2019-03-29 2024-07-04 메디뮨 리미티드 화합물 및 이의 접합체

Similar Documents

Publication Publication Date Title
JP7447183B2 (ja) 親水性抗体-薬物コンジュゲート
HRP20221280T1 (hr) Spojevi i njihovi konjugati
JP2023512501A5 (cg-RX-API-DMAC7.html)
JP6117921B2 (ja) 細胞毒性剤と細胞結合受容体との共役体
JP6843080B2 (ja) システイン改変抗体の複合体
JP2025510629A (ja) カンプトテシンコンジュゲート
CA2944699C (en) Affinity medicant conjugates
JP2017537893A5 (cg-RX-API-DMAC7.html)
CA3207893A1 (en) Immunomodulatory antibody-drug conjugates
EA037203B1 (ru) Конъюгаты антитело-лекарственное средство с самостабилизирующимися линкерами
JP2021536430A (ja) リンカー、それを含む抗体薬物コンジュゲート、およびその使用
JP2020512276A (ja) ベンゾジアゼピン誘導体の選択的スルホン化
CN112601522A (zh) 抗体-alk5抑制剂偶联物及其用途
JP2023511184A5 (cg-RX-API-DMAC7.html)
CA3164037A1 (en) Alk5 inhibitor conjugates and uses thereof
JP2017160205A (ja) 細胞毒性剤と細胞結合受容体との共役体
CN114269388A (zh) 抗体-alk5抑制剂缀合物及其用途
US12280021B2 (en) Affinity medicant conjugate
WO2024023735A1 (en) Auristatin derivatives and conjugates thereof
JP5341314B2 (ja) 薬物送出系
US20250241872A1 (en) Affinity medicant conjugate
HK40065597A (en) Hydrophilic drug-linker compounds
JP2019167359A (ja) 細胞毒性剤と細胞結合受容体との共役体
NZ722252B2 (en) Hydrophilic antibody-drug conjugates
NZ761642B2 (en) Hydrophilic antibody-drug conjugates